



ASX ANNOUNCEMENT

5 January 2021

Cann Group secures exclusive supply position with a strategic investment in iuvo Therapeutics Limited; receives initial 19,000 unit order for Europe

5 January 2021 - Cann Group Limited (ASX: CAN) today announced that it has committed to a minority investment in iuvo Therapeutics Limited ('iuvo'), a leading independent German GMP certified importer and distributor of medicinal cannabis products throughout Europe and has received an initial order to ship 19,000 units of 30ml extract.

Cann Group has made a strategic CAD 1 million cornerstone commitment in a CAD5 million capital raising that is currently being completed by iuvo, resulting in Cann Group holding approximately 2% of iuvo's issued ordinary shares. Funds raised will be used by iuvo to expand sales and marketing capabilities and assist with construction of a new manufacturing and formulation facility in Malta.

Following the investment, Cann Group will be granted exclusive external rights to supply iuvo Therapeutics GmbH, iuvo's wholly-owned subsidiary, ('iuvo Germany'), with medicinal cannabis extracts until 31 December 2021, with those rights then converting to preferred non-exclusive status.

iuvo has placed an initial 19,000 unit order for Cann product which is expected to be shipped to Germany within the next month, subject to relevant regulatory clearances. Being fully compliant with the latest German monograph addition "Cannabis Extractum Normatum", it will be one of the first full-spectrum extracts available in the market.

"This strategic investment will enable iuvo to expand its patient reach throughout Germany and Europe. Cann Group's extracts are manufactured from Australian GMP Cannabis flower, providing regulatory, investment and supply security in a market with superior pharmaceutical standards," said Daniel Seidl, Managing Director of iuvo.

iuvo Therapeutics Limited is a pharmaceutical company focused on providing a diversified portfolio of medical cannabis products for European patients and, within the German territory, has access to over 20,000 pharmacies. Germany is Europe's largest medicinal cannabis market with 2019 sales exceeding those of all other European markets combined.

Cann Group CEO, Peter Crock, said the exclusive supply arrangements significantly increase the value and importance of the three-year supply agreement with iuvo Germany, which was signed in May 2020.

"We believe this initial order represents the largest shipment of product produced in Australia for export markets and is a tangible sign of iuvo's commitment to servicing its growing customer base with safe, quality GMP standard medicinal cannabis."



Authorised for release by the Board of Directors, Cann Group Limited.

For further information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@cann grouplimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088
clive.fanning@cann grouplimited.com

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. The company has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation facility near Mildura, Victoria. Cann Group has executed collaboration agreements that have enabled it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products. **Learn more about Cann Group at www.cann grouplimited.com**